PRESS RELEASE

Q4 2021 — Press release

Q4 2021PDF · 20 pages517 KB
FOR IMMEDIATE RELEASE
• 2021 Fourth-Quarter Sales of $24.8 Billion reflecting growth of 10.4%, operational sales growth of 11.6%*,
and adjusted operational sales growth of 12.3%*
• 2021 Full-Year Sales of $93.8 Billion reflecting growth of 13.6%, operational sales growth of 12.2%*, and
adjusted operational sales growth of 12.8%*
• 2021 Fourth-Quarter EPS of $1.77 increased 172.3%; adjusted EPS of $2.13 increased 14.5%*
• 2021 Full-Year EPS of $7.81 increased 41.7%; adjusted EPS of $9.80 increased 22.0%*
• Company guides 2022 adjusted operational sales growth of 7.7%* and adjusted operational EPS growth of
9.2%*
New Brunswick, N.J. (January 25, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-
quarter and full year 2021. “Our 2021 performance reflects continued strength across all segments of our business.
Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to
deliver life-changing solutions to consumers, patients, and health care providers” said Joaquin Duato, Chief Executive
Officer. “Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022
and beyond.”
OVERALL FINANCIAL RESULTS
($ in Millions, except EPS) 2021 2020 % Change 2021 2020 % Change
Reported Sales 24,804	$ 22,475	$ 10.4% 93,775	$ 82,584	$ 13.6%
Net Earnings 4,736 1,738 172.5% 20,878 14,714 41.9%
EPS (diluted) 1.77	$ 0.65	$ 172.3% 7.81	$ 5.51	$ 41.7%
Non-GAAP* ($ in Millions, except EPS) 2021 2020 % Change 2021 2020 % Change
Operational Sales 1,2 11.6% 12.2%
Adjusted Operational Sales 1,3 12.3% 12.8%
Adjusted Net Earnings 1,4 5,678 4,965 14.4% 26,195 21,433 22.2%
Adjusted EPS (diluted)1,4 2.13	$ 1.86	$ 14.5% 9.80	$ 8.03	$ 22.0%
Q4 Full Year
Q4 Full Year

-- 1 of 20 --

REGIONAL SALES RESULTS
SEGMENT SALES RESULTS
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items
Note: values may have been rounded
Q4
($ in Millions) 2021 2020 Reported Operational1,2 Currency
Adjusted
Operational1,3
U.S. 12,163	$ 11,809	$ 3.0% 3.0 - 3.1
International 12,641 10,666 18.5% 21.2 (2.7) 22.4
Worldwide 24,804	$ 22,475	$ 10.4% 11.6 (1.2) 12.3
Full Year
($ in Millions) 2021 2020 Reported Operational1,2 Currency
Adjusted
Operational1,3
U.S. 47,156	$ 43,133	$ 9.3% 9.3 - 9.5
International 46,619 39,451 18.2% 15.3 2.9 16.6
Worldwide 93,775	$ 82,584	$ 13.6% 12.2 1.4 12.8
% Change
% Change
Q4
($ in Millions) 2021 2020 Reported Operational1,2 Currency
Adjusted
Operational1,3
Consumer Health 3,657	$ 3,618	$ 1.1% 1.8 (0.7) 2.9
Pharmaceutical 14,288 12,268 16.5% 17.9 (1.4) 18.6
Medical Devices 6,859 6,589 4.1% 5.3 (1.2) 5.6
Worldwide 24,804	$ 22,475	$ 10.4% 11.6 (1.2) 12.3
Full Year
($ in Millions) 2021 2020 Reported Operational1,2 Currency
Adjusted
Operational1,3
Consumer Health 14,635	$ 14,053	$ 4.1% 2.8 1.3 3.8
Pharmaceutical 52,080 45,572 14.3% 13.1 1.2 13.6
Medical Devices 27,060 22,959 17.9% 16.2 1.7 16.8
Worldwide 93,775	$ 82,584	$ 13.6% 12.2 1.4 12.8
% Change
% Change

-- 2 of 20 --

FULL YEAR 2021 SEGMENT COMMENTARY:
Consumer Health
Consumer Health worldwide adjusted operational sales increased 3.8%* primarily driven by over-the-counter (OTC)
products including TYLENOL analgesics and digestive health, in addition to NEUTROGENA and AVEENO products
in Skin Health / Beauty primarily due to COVID-19 market recovery. The growth was partially offset by external supply
constraints mainly impacting Skin Health / Beauty.
Pharmaceutical
Pharmaceutical worldwide adjusted operational sales grew 13.6%* driven by DARZALEX (daratumumab), a biologic
for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-
mediated inflammatory diseases, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate
to severe plaque psoriasis, and for adults with active psoriatic arthritis, ERLEADA (apalutamide), a next-generation
androgen receptor inhibitor for the treatment of patients with prostate cancer, and INVEGA
SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical
antipsychotics for the treatment of schizophrenia in adults. Also contributing to growth were sales of th e Janssen
COVID-19 Vaccine (Ad26.COV2.S) for the treatment of the SARS-CoV-2 virus. This growth was partially offset by
declines in U.S. sales of REMICADE (infliximab), a biologic approved for the treatment of a number of immune-
mediated inflammatory diseases.
Medical Devices
Medical Devices worldwide adjusted operational sales grew 16.8%*, driven primarily by the market recovery from
COVID-19 impacts and the associated deferral of medical procedures in the prior year across all of our businesses
including Surgery, Interventional Solutions, Vision and Orthopaedics.

-- 3 of 20 --

NOTABLE NEW ANNOUCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures
filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on
Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov,
www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases
and information available in the Investors section of the company’s website at news releases,as well as
www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and www.LTLManagementInformation.com.
Regulatory
Decisions
European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for
the Maintenance Treatment of Schizophrenia in Adults (press release)
U.S. FDA Approves DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in
Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After
First or Subsequent Relapse
(press release)
Janssen EMEA Receives Conditional Marketing Authorisation for RYBREVANT®
(amivantamab), the First Treatment Approved for Patients with Advanced NonSmall Cell
Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations After Failure of Platinum-
Based Therapy
(press release)
Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S.
FDA (press release)
World Health Organization Strategic Advisory Group of Experts (SAGE) Interim
Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster (press release)
Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19
Vaccine (press release)
FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat
Blood Clots in Pediatric Patients (press release)
U.S. FDA Approves New MENTOR® MemoryGel BOOST™ Breast Implant1 (press release)
Regulatory
Submissions
Janssen Seeks Approval of IMBRUVICA® (ibrutinib) in a Fixed-Duration Regimen for
Patients with Untreated Chronic Lymphocytic Leukaemia (CLL) (EU) (press release)
Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of
Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (press release)
Other
Johnson & Johnson Announces Plans to Accelerate Innovation, Serve Patients and
Consumers, and Unlock Value through Intent to Separate Consumer Health Business (press release)
Johnson & Johnson Appoints Senior Leaders to Executive Committee (press release)
Johnson & Johnson announces significant progress towards its climate goals – 100%
renewable electricity for all sites in the United States, Canada and Europe by 2023 (press release)
Johnson & Johnson Medical Devices Companies Announces Strategic Partnership with
Microsoft to Further Enable its Digital Surgery Solutions1 (press release)

-- 4 of 20 --

Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen
of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses (press release)
Johnson & Johnson Enters into Agreement to Provide its Single-Shot COVID-19 Vaccine for
the World’s Most Vulnerable People through Novel Humanitarian Buffer (press release)
Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against
Hospitalization in South Africa when Omicron was Dominant (press release)
1Subsequent to the quarter
FULL-YEAR 2022 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is
unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses,
acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These
items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in
accordance with GAAP.
($ in Billions, except EPS) January 2022
(ex. COVID Vx)
January 2022
(COVID Vx)
January 2022
(incl. COVID Vx)
Adjusted Operational
Sales1,2
Change vs. Prior Year
6.5% – 7.5% 7.0% – 8.5%
Operational Sales2
Change vs. Prior Year
$97.3B – $98.3B
6.5% – 7.5%
$3.0B - $3.5B $100.3B – $101.8B
7.0% – 8.5%
Estimated Reported Sales3
Change vs. Prior Year
$95.9B - $96.9B
5.0% – 6.0%
$3.0B - $3.5B $98.9B - $100.4B
5.5% – 7.0%
Adjusted Operational EPS
(Diluted)2,4
Change vs. Prior Year
$10.60 - $10.80
8.2% – 10.2%
Adjusted EPS (Diluted)3,4
Change vs. Prior Year
$10.40 - $10.60
6.1% – 8.2%
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: January 2022 = $1.14 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items
Note: % may have been rounded

-- 5 of 20 --

Other modeling considerations will be provided on the webcast.
WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m.,
Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by
visiting the Johnson & Johnson Website. A replay and podcast will be available approximately two hours after the live
webcast in the Investors section of the company's website at events-and-presentations.
ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward
progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of
life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach
and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy
mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity
to profoundly change the trajectory of health for humanity.
NON-GAAP FINANCIAL MEASURES:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth”
excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”,
“adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax
intangible amortization expense and special items, are non-GAAP financial measures and should not be considered
replacements for, and should be read together with, the most comparable GAAP financial measures. Except for
guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP
financial measures can be found in the accompanying financial schedules of the earnings release and the Investors
section of the company's website at quarterly-results.
Copies of the financial schedules accompanying this earnings release are available on the company’s website at
quarterly-results. These schedules include supplementary sales data, a condensed consolidated statement of
earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional
information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of
selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in
the Investors section of the company's website at quarterly-results.

-- 6 of 20 --

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of
1995 regarding, among other things: future operating and financial performance, product development, market
position, business strategy, and the anticipated separation of the company’s Consumer Health business. The reader
is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize,
actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and
uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the
scope and duration of the outbreak, government actions and restrictive measures implemented in response, material
delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on
the company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic; economic factors,
such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new
products and patents attained by competitors; challenges inherent in new product research and development,
including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for
new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to
successfully execute strategic plans, including restructuring plans; the impact of business combinations and
divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety
concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including
related to product liability claims; changes to applicable laws and regulations, including tax laws and global health
care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers
of health care products and services; financial instability of international economies and legal systems and sovereign
risk; increased scrutiny of the health care industry by government agencies; the company’s ability to satisfy the
necessary conditions to consummate the separation of the company’s Consumer Health business on a timely basis
or at all; the company’s ability to successfully separate the company’s Consumer Health business and realize the
anticipated benefits from the separation; and the New Consumer Health Company’s ability to succeed as a standalone
publicly traded company. A further list and descriptions of these risks, uncertainties and other factors can be found in
Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021 including in the sections
captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the
company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange
Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson &
Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson &
Johnson does not undertake to update any forward-looking statement as a result of new information or future events
or developments.
Press Contacts: Investor Contacts:
Lindsay Hymson Jessica Moore Sarah Wood
(516) 524-1757 (732) 524-2955 (732) 524-2617

-- 7 of 20 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2021 	2020 	Total 	Operations 	Currency 	2021 	2020 	Total 	Operations 	Currency
Sales to customers by
segment of business
Consumer Health
U.S. 	1,529	$ 	1,509 	1.3 % 	1.3 	- 	6,516	$ 	6,362 	2.4 % 	2.4 	-
International 	2,128 	2,109 	0.9 	2.1 	(1.2) 	8,119 	7,691 	5.6 	3.1 	2.5
3,657 	3,618 	1.1 	1.8 	(0.7) 	14,635 	14,053 	4.1 	2.8 	1.3
Pharmaceutical
U.S. 	7,418 	7,116 	4.2 	4.2 	- 	27,954 	25,735 	8.6 	8.6 	-
International 	6,870 	5,152 	33.4 	36.9 	(3.5) 	24,126 	19,837 	21.6 	18.8 	2.8
14,288 	12,268 	16.5 	17.9 	(1.4) 	52,080 	45,572 	14.3 	13.1 	1.2
Medical Devices
U.S. 	3,216 	3,184 	1.0 	1.0 	- 	12,686 	11,036 	14.9 	14.9 	-
International 	3,643 	3,405 	7.0 	9.3 	(2.3) 	14,374 	11,923 	20.6 	17.3 	3.3
6,859 	6,589 	4.1 	5.3 	(1.2) 	27,060 	22,959 	17.9 	16.2 	1.7
U.S. 	12,163 	11,809 	3.0 	3.0 	- 	47,156 	43,133 	9.3 	9.3 	-
International 	12,641 	10,666 	18.5 	21.2 	(2.7) 	46,619 	39,451 	18.2 	15.3 	2.9
Worldwide 	24,804	$ 	22,475 	10.4 % 	11.6 	(1.2) 	93,775	$ 	82,584 	13.6 % 	12.2 	1.4
Note: Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
FOURTH QUARTER 	TWELVE MONTHS
Percent Change

-- 8 of 20 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2021 	2020 	Total 	Operations 	Currency 	2021 	2020 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	12,163	$ 	11,809 	3.0 % 	3.0 	- 	47,156	$ 	43,133 	9.3 % 	9.3 	-
Europe 	6,925 	5,271 	31.4 	34.7 	(3.3) 	23,594 	18,980 	24.3 	20.7 	3.6
Western Hemisphere excluding U.S. 	1,459 	1,404 	3.9 	5.0 	(1.1) 	5,750 	5,335 	7.8 	7.3 	0.5
Asia-Pacific, Africa 	4,257 	3,991 	6.6 	9.0 	(2.4) 	17,275 	15,136 	14.1 	11.4 	2.7
International 	12,641 	10,666 	18.5 	21.2 	(2.7) 	46,619 	39,451 	18.2 	15.3 	2.9
Worldwide 	24,804	$ 	22,475 	10.4 % 	11.6 	(1.2) 	93,775	$ 	82,584 	13.6 % 	12.2 	1.4
Note: Percentages have been calculated using actual, non-rounded figures
and, therefore, may not recalculate precisely.
FOURTH QUARTER 	TWELVE MONTHS
Percent Change

-- 9 of 20 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	24,804	$ 	100.0 	22,475	$ 	100.0 	10.4
Cost of products sold 	7,955 	32.1 	7,814 	34.8 	1.8
Gross Profit 	16,849 	67.9 	14,661 	65.2 	14.9
Selling, marketing and administrative expenses 	7,154 	28.9 	6,457 	28.7 	10.8
Research and development expense 	4,720 	19.0 	4,032 	17.9 	17.1
In-process research and development 	0 	0.0 	37 	0.2
Interest (income) expense, net 	47 	0.2 	74 	0.3
Other (income) expense, net 	9 	0.0 	2,354 	10.5
Restructuring 	83 	0.3 	60 	0.3
Earnings before provision for taxes on income 	4,836 	19.5 	1,647 	7.3 	193.6
Provision for/(Benefit from) taxes on income 	100 	0.4 	(91) 	(0.4) 	(209.9)
Net earnings 	4,736	$ 	19.1 	1,738	$ 	7.7 	172.5
Net earnings per share (Diluted) 	1.77	$ 	0.65	$ 	172.3
Average shares outstanding (Diluted) 	2,670.2 	2,669.2
Effective tax rate 	2.1 % 	(5.5) %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 	6,339	$ 	25.6 	5,601	$ 	24.9 	13.2
Net earnings 	5,678	$ 	22.9 	4,965	$ 	22.1 	14.4
Net earnings per share (Diluted) 	2.13	$ 	1.86	$ 	14.5
Effective tax rate 	10.4 % 	11.4 %
(1) See Reconciliation of Non-GAAP Financial Measures.
FOURTH QUARTER
2021 	2020

-- 10 of 20 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	93,775	$ 	100.0 	82,584	$ 	100.0 	13.6
Cost of products sold 	29,855 	31.8 	28,427 	34.4 	5.0
Gross Profit 	63,920 	68.2 	54,157 	65.6 	18.0
Selling, marketing and administrative expenses 	24,659 	26.3 	22,084 	26.8 	11.7
Research and development expense 	14,714 	15.7 	12,159 	14.7 	21.0
In-process research and development 	900 	1.0 	181 	0.2
Interest (income) expense, net 	130 	0.1 	90 	0.1
Other (income) expense, net 	489 	0.5 	2,899 	3.5
Restructuring 	252 	0.3 	247 	0.3
Earnings before provision for taxes on income 	22,776 	24.3 	16,497 	20.0 	38.1
Provision for taxes on income 	1,898 	2.0 	1,783 	2.2 	6.4
Net earnings 	20,878	$ 	22.3 	14,714	$ 	17.8 	41.9
Net earnings per share (Diluted) 	7.81	$ 	5.51	$ 	41.7
Average shares outstanding (Diluted) 	2,674.0 	2,670.7
Effective tax rate 	8.3 % 	10.8 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 	30,464	$ 	32.5 	25,428	$ 	30.8 	19.8
Net earnings 	26,195	$ 	27.9 	21,433	$ 	26.0 	22.2
Net earnings per share (Diluted) 	9.80	$ 	8.03	$ 	22.0
Effective tax rate 	14.0 % 	15.7 %
(1) See Reconciliation of Non-GAAP Financial Measures.
TWELVE MONTHS
2021 	2020

-- 11 of 20 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2021 	2020 	2021 	2020
Net Earnings, after tax- as reported 	$4,736 	$1,738 	$20,878 	$14,714
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,121 	1,234 	4,697 	4,660
Litigation expense, net 	274 	2,902 	2,328 	5,112
IPR&D 	- 	37 	900 	181
Restructuring related 	140 	85 	473 	448
Acquisition, integration and divestiture related ¹ 	26 	14 	(478) 	(1,073)
(Gains)/losses on securities 	(198) 	(373) 	(533) 	(547)
Medical Device Regulation 	73 	55 	234 	144
Consumer Health separation costs 	67 	- 	67 	-
Other 	- 	- 	- 	6
Tax Adjustments
Tax impact on special item adjustments 2 	(184) 	(606) 	(1,281) 	(1,608)
Tax legislation and other tax related 	(377) 	(121) 	(1,090) 	(604)
Adjusted Net Earnings, after tax 	$5,678 	$4,965 	$26,195 	$21,433
Average shares outstanding (Diluted) 	2,670.2 	2,669.2 	2,674.0 	2,670.7
Adjusted net earnings per share (Diluted) 	$2.13 	$1.86 	$9.80 	$8.03
Operational adjusted net earnings per share (Diluted) 	$2.18 	$9.65
Notes:
1
2 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the
above pre-tax special items in arriving at adjusted earnings.
Fourth Quarter 	Twelve Months Ended
Acquisition, integration and divestiture related for 2021 primarily includes the gain on the divestiture of two
Pharmaceutical brands outside of the U.S. Acquisition, integration and divestiture related for 2020 primarily includes a
Contingent Consideration reversal of $1,148M related to the timing of certain developmental milestones associated
with the Auris Health acquisition.

-- 12 of 20 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	1.1% 	16.5% 	4.1% 	10.4%
U.S. 	1.3% 	4.2% 	1.0% 	3.0%
International 	0.9% 	33.4% 	7.0% 	18.5%
WW Currency 	(0.7) 	(1.4) 	(1.2) 	(1.2)
U.S. 	- 	- 	- 	-
International 	(1.2) 	(3.5) 	(2.3) 	(2.7)
WW Operational 	1.8% 	17.9% 	5.3% 	11.6%
U.S. 	1.3% 	4.2% 	1.0% 	3.0%
International 	2.1% 	36.9% 	9.3% 	21.2%
General Surgery
Advanced Sterilization Products 	0.3 	0.1
U.S. 	0.0 	0.0
International 	0.5 	0.2
Skin Health / Beauty
Dr. Ci Labo - Sedona 	0.7 	0.1
U.S. 	0.0 	0.0
International 	1.2 	0.3
All Other Acquisitions and Divestitures 	0.4 	0.7 	0.1 	0.4
U.S. 	0.6 	0.0 	0.2 	0.1
International 	0.3 	1.7 	0.0 	0.8
WW Adjusted Operational 	2.9% 	18.6% 	5.6% 	12.3%
U.S. 	1.9% 	4.2% 	1.2% 	3.1%
International 	3.6% 	38.6% 	9.8% 	22.4%
Adjusted Operational Sales Growth
FOURTH QUARTER 2021 ACTUAL vs. 2020 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 13 of 20 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	4.1% 	14.3% 	17.9% 	13.6%
U.S. 	2.4% 	8.6% 	14.9% 	9.3%
International 	5.6% 	21.6% 	20.6% 	18.2%
WW Currency 	1.3 	1.2 	1.7 	1.4
U.S. 	- 	- 	- 	-
International 	2.5 	2.8 	3.3 	2.9
WW Operational 	2.8% 	13.1% 	16.2% 	12.2%
U.S. 	2.4% 	8.6% 	14.9% 	9.3%
International 	3.1% 	18.8% 	17.3% 	15.3%
General Surgery
Advanced Sterilization Products 	0.5 	0.1
U.S. 	0.0 	0.0
International 	1.0 	0.3
Skin Health / Beauty
Dr. Ci Labo - Sedona 	0.5 	0.1
U.S. 	0.0 	0.0
International 	1.0 	0.2
All Other Acquisitions and Divestitures 	0.4 	0.5 	0.1 	0.4
U.S. 	0.6 	0.0 	0.4 	0.2
International 	0.3 	1.4 	0.0 	0.8
WW Adjusted Operational 	3.8% 	13.6% 	16.8% 	12.8%
U.S. 	3.0% 	8.6% 	15.3% 	9.5%
International 	4.4% 	20.2% 	18.3% 	16.6%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
TWELVE MONTHS 2021 ACTUAL vs. 2020 ACTUAL
Segments

-- 14 of 20 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US 	633	$ 	543 	16.8% 	16.8% 	- 	2,594	$ 	2,460 	5.4% 	5.4% 	-
Intl 	740 	642 	15.1% 	14.9% 	0.2% 	2,634 	2,364 	11.4% 	6.9% 	4.5%
WW 	1,373 	1,185 	15.9% 	15.8% 	0.1% 	5,227 	4,824 	8.4% 	6.2% 	2.2%
SKIN HEALTH / BEAUTY
US 	538 	583 	-7.8% 	-7.8% 	- 	2,400 	2,350 	2.1% 	2.1% 	-
Intl 	546 	594 	-8.2% 	-6.4% 	-1.8% 	2,141 	2,100 	1.9% 	-0.3% 	2.2%
WW 	1,084 	1,177 	-8.0% 	-7.1% 	-0.9% 	4,541 	4,450 	2.0% 	1.0% 	1.0%
ORAL CARE
US 	159 	173 	-8.2% 	-8.2% 	- 	637 	683 	-6.7% 	-6.7% 	-
Intl 	246 	264 	-7.2% 	-5.5% 	-1.7% 	1,008 	958 	5.1% 	2.8% 	2.3%
WW 	405 	437 	-7.6% 	-6.5% 	-1.1% 	1,645 	1,641 	0.2% 	-1.2% 	1.4%
BABY CARE
US 	90 	97 	-7.5% 	-7.5% 	- 	378 	376 	0.5% 	0.5% 	-
Intl 	309 	310 	-0.3% 	1.3% 	-1.6% 	1,188 	1,141 	4.1% 	3.7% 	0.4%
WW 	399 	407 	-2.0% 	-0.8% 	-1.2% 	1,566 	1,517 	3.2% 	2.9% 	0.3%
WOMEN'S HEALTH
US 	4 	3 	14.1% 	14.1% 	- 	13 	13 	-1.6% 	-1.6% 	-
Intl 	230 	234 	-1.8% 	1.2% 	-3.0% 	905 	888 	1.8% 	2.0% 	-0.2%
WW 	233 	237 	-1.6% 	1.3% 	-2.9% 	917 	901 	1.8% 	1.9% 	-0.1%
WOUND CARE / OTHER
US 	106 	110 	-4.2% 	-4.2% 	- 	495 	480 	3.1% 	3.1% 	-
Intl 	57 	65 	-9.6% 	-10.2% 	0.6% 	243 	240 	1.7% 	-2.7% 	4.4%
WW 	164 	175 	-6.2% 	-6.4% 	0.2% 	739 	720 	2.6% 	1.2% 	1.4%
TOTAL CONSUMER HEALTH
US 	1,529 	1,509 	1.3% 	1.3% 	- 	6,516 	6,362 	2.4% 	2.4% 	-
Intl 	2,128 	2,109 	0.9% 	2.1% 	-1.2% 	8,119 	7,691 	5.6% 	3.1% 	2.5%
WW 	3,657	$ 	3,618 	1.1% 	1.8% 	-0.7% 	14,635	$ 	14,053 	4.1% 	2.8% 	1.3%
See footnotes at end of schedule
% Change 	% Change

-- 15 of 20 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
PHARMACEUTICAL SEGMENT (2,3) 	2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
IMMUNOLOGY
US 	2,912	$ 	2,845 	2.4% 	2.4% 	- 	10,843	$ 	10,175 	6.6% 	6.6% 	-
Intl 	1,443 	1,261 	14.5% 	17.9% 	-3.4% 	5,907 	4,880 	21.0% 	17.7% 	3.3%
WW 	4,355 	4,105 	6.1% 	7.1% 	-1.0% 	16,750 	15,055 	11.3% 	10.2% 	1.1%
REMICADE
US 	511 	656 	-22.2% 	-22.2% 	- 	2,019 	2,508 	-19.5% 	-19.5% 	-
US Exports (4) 	39 	25 	53.5% 	53.5% 	- 	236 	346 	-31.9% 	-31.9% 	-
Intl 	214 	220 	-2.3% 	-2.4% 	0.1% 	935 	893 	4.8% 	0.4% 	4.4%
WW 	764 	901 	-15.2% 	-15.2% 	0.0% 	3,190 	3,747 	-14.9% 	-15.9% 	1.0%
SIMPONI / SIMPONI ARIA
US 	287 	315 	-8.9% 	-8.9% 	- 	1,127 	1,155 	-2.4% 	-2.4% 	-
Intl 	271 	261 	3.6% 	8.4% 	-4.8% 	1,148 	1,088 	5.5% 	4.1% 	1.4%
WW 	559 	576 	-3.2% 	-1.0% 	-2.2% 	2,276 	2,243 	1.4% 	0.8% 	0.6%
STELARA
US 	1,542 	1,572 	-1.9% 	-1.9% 	- 	5,938 	5,240 	13.3% 	13.3% 	-
Intl 	792 	672 	17.9% 	21.7% 	-3.8% 	3,196 	2,467 	29.6% 	25.9% 	3.7%
WW 	2,334 	2,244 	4.0% 	5.1% 	-1.1% 	9,134 	7,707 	18.5% 	17.3% 	1.2%
TREMFYA
US 	528 	276 	90.9% 	90.9% 	- 	1,503 	926 	62.3% 	62.3% 	-
Intl 	165 	105 	56.9% 	61.8% 	-4.9% 	624 	421 	48.2% 	44.0% 	4.2%
WW 	693 	382 	81.5% 	82.8% 	-1.3% 	2,127 	1,347 	57.9% 	56.5% 	1.4%
OTHER IMMUNOLOGY
US 	6 	- 	* 	* 	- 	21 	- 	* 	* 	-
Intl 	0 	2 	* 	* 	* 	3 	11 	-73.3% 	-74.6% 	1.3%
WW 	6 	2 	* 	* 	* 	24 	11 	* 	* 	*
INFECTIOUS DISEASES
US 	614 	470 	30.8% 	30.8% 	- 	2,249 	1,735 	29.7% 	29.7% 	-
Intl 	1,824 	442 	* 	* 	-3.0% 	3,612 	1,839 	96.3% 	93.4% 	2.9%
WW 	2,437 	912 	* 	* 	-1.5% 	5,861 	3,574 	64.0% 	62.5% 	1.5%
COVID-19 VACCINE
US 	213 	- 	* 	* 	- 	634 	- 	* 	* 	-
Intl 	1,405 	- 	* 	* 	- 	1,751 	- 	* 	* 	-
WW 	1,619 	- 	* 	* 	- 	2,385 	- 	* 	* 	-
EDURANT / rilpivirine
US 	10 	11 	-15.8% 	-15.8% 	- 	41 	44 	-7.6% 	-7.6% 	-
Intl 	220 	236 	-6.8% 	-3.3% 	-3.5% 	953 	920 	3.6% 	0.4% 	3.2%
WW 	230 	248 	-7.2% 	-3.9% 	-3.3% 	994 	964 	3.1% 	0.0% 	3.1%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	380 	433 	-12.2% 	-12.2% 	- 	1,508 	1,587 	-4.9% 	-4.9% 	-
Intl 	135 	136 	-0.1% 	3.0% 	-3.1% 	575 	597 	-3.6% 	-6.0% 	2.4%
WW 	515 	569 	-9.3% 	-8.5% 	-0.8% 	2,083 	2,184 	-4.6% 	-5.2% 	0.6%
OTHER INFECTIOUS DISEASES
US 	11 	25 	-55.9% 	-55.9% 	- 	66 	104 	-36.0% 	-36.0% 	-
Intl 	63 	71 	-10.9% 	-10.0% 	-0.9% 	333 	323 	3.0% 	-0.1% 	3.1%
WW 	74 	96 	-22.9% 	-22.2% 	-0.7% 	399 	427 	-6.5% 	-8.9% 	2.4%
% Change 	% Change

-- 16 of 20 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
NEUROSCIENCE
US 	899 	806 	11.4% 	11.4% 	- 	3,347 	3,091 	8.3% 	8.3% 	-
Intl 	894 	892 	0.2% 	3.2% 	-3.0% 	3,664 	3,457 	6.0% 	3.9% 	2.1%
WW 	1,793 	1,698 	5.5% 	7.1% 	-1.6% 	7,011 	6,548 	7.1% 	5.9% 	1.2%
CONCERTA / Methylphenidate
US 	55 	33 	68.1% 	68.1% 	- 	172 	183 	-5.8% 	-5.8% 	-
Intl 	123 	120 	3.2% 	6.0% 	-2.8% 	495 	439 	12.8% 	10.1% 	2.7%
WW 	178 	153 	17.2% 	19.4% 	-2.2% 	667 	622 	7.3% 	5.4% 	1.9%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	668 	610 	9.5% 	9.5% 	- 	2,550 	2,314 	10.2% 	10.2% 	-
Intl 	361 	355 	1.5% 	5.0% 	-3.5% 	1,472 	1,339 	10.0% 	6.9% 	3.1%
WW 	1,029 	965 	6.5% 	7.8% 	-1.3% 	4,022 	3,653 	10.1% 	9.0% 	1.1%
RISPERDAL CONSTA
US 	77 	76 	2.3% 	2.3% 	- 	287 	296 	-2.9% 	-2.9% 	-
Intl 	63 	92 	-30.3% 	-26.4% 	-3.9% 	305 	346 	-11.8% 	-13.1% 	1.3%
WW 	140 	167 	-15.6% 	-13.4% 	-2.2% 	592 	642 	-7.7% 	-8.4% 	0.7%
OTHER NEUROSCIENCE
US 	99 	88 	11.7% 	11.7% 	- 	338 	298 	13.3% 	13.3% 	-
Intl 	346 	326 	6.2% 	8.6% 	-2.4% 	1,391 	1,334 	4.3% 	3.2% 	1.1%
WW 	445 	414 	7.4% 	9.2% 	-1.8% 	1,729 	1,632 	6.0% 	5.0% 	1.0%
ONCOLOGY
US 	1,594 	1,469 	8.5% 	8.5% 	- 	5,958 	5,092 	17.0% 	17.0% 	-
Intl 	2,184 	1,965 	11.1% 	15.2% 	-4.1% 	8,590 	7,275 	18.1% 	15.3% 	2.8%
WW 	3,778 	3,434 	10.0% 	12.3% 	-2.3% 	14,548 	12,367 	17.6% 	16.0% 	1.6%
DARZALEX
US 	867 	692 	25.3% 	25.3% 	- 	3,169 	2,232 	42.0% 	42.0% 	-
Intl 	778 	561 	38.9% 	43.5% 	-4.6% 	2,854 	1,958 	45.8% 	42.6% 	3.2%
WW 	1,645 	1,253 	31.4% 	33.4% 	-2.0% 	6,023 	4,190 	43.8% 	42.3% 	1.5%
ERLEADA
US 	235 	176 	33.4% 	33.4% 	- 	813 	583 	39.3% 	39.3% 	-
Intl 	149 	64 	* 	* 	* 	478 	176 	* 	* 	*
WW 	384 	241 	59.8% 	61.3% 	-1.5% 	1,291 	760 	70.0% 	68.7% 	1.3%
IMBRUVICA
US 	436 	492 	-11.3% 	-11.3% 	- 	1,747 	1,821 	-4.0% 	-4.0% 	-
Intl 	626 	625 	0.0% 	3.4% 	-3.4% 	2,622 	2,307 	13.6% 	10.4% 	3.2%
WW 	1,062 	1,117 	-5.0% 	-3.1% 	-1.9% 	4,369 	4,128 	5.8% 	4.1% 	1.7%
ZYTIGA / abiraterone acetate
US 	23 	89 	-74.2% 	-74.2% 	- 	119 	373 	-68.1% 	-68.1% 	-
Intl 	525 	533 	-1.4% 	3.1% 	-4.5% 	2,178 	2,097 	3.9% 	1.5% 	2.4%
WW 	548 	622 	-11.8% 	-7.9% 	-3.9% 	2,297 	2,470 	-7.0% 	-9.0% 	2.0%
OTHER ONCOLOGY
US 	34 	20 	64.7% 	64.7% 	- 	110 	83 	31.7% 	31.7% 	-
Intl 	106 	183 	-42.0% 	-39.2% 	-2.8% 	458 	738 	-37.9% 	-38.7% 	0.8%
WW 	140 	202 	-31.3% 	-28.8% 	-2.5% 	568 	821 	-30.8% 	-31.5% 	0.7%
% Change 	% Change

-- 17 of 20 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
PULMONARY HYPERTENSION
US 	587 	592 	-0.7% 	-0.7% 	- 	2,365 	2,133 	10.9% 	10.9% 	-
Intl 	264 	273 	-3.6% 	0.8% 	-4.4% 	1,085 	1,015 	6.9% 	5.5% 	1.4%
WW 	851 	865 	-1.6% 	-0.2% 	-1.4% 	3,450 	3,148 	9.6% 	9.2% 	0.4%
OPSUMIT
US 	286 	279 	2.0% 	2.0% 	- 	1,147 	1,008 	13.7% 	13.7% 	-
Intl 	162 	173 	-6.1% 	-1.7% 	-4.4% 	672 	631 	6.6% 	5.1% 	1.5%
WW 	448 	452 	-1.1% 	0.6% 	-1.7% 	1,819 	1,639 	11.0% 	10.4% 	0.6%
UPTRAVI
US 	264 	263 	0.0% 	0.0% 	- 	1,056 	955 	10.5% 	10.5% 	-
Intl 	46 	38 	21.9% 	24.7% 	-2.8% 	181 	138 	31.1% 	27.0% 	4.1%
WW 	310 	301 	2.7% 	3.1% 	-0.4% 	1,237 	1,093 	13.1% 	12.6% 	0.5%
OTHER PULMONARY HYPERTENSION
US 	38 	49 	-20.1% 	-20.1% 	- 	163 	169 	-3.7% 	-3.7% 	-
Intl 	56 	63 	-12.2% 	-6.6% 	-5.6% 	232 	247 	-5.9% 	-5.4% 	-0.5%
WW 	94 	112 	-15.6% 	-12.4% 	-3.2% 	395 	416 	-5.0% 	-4.7% 	-0.3%
CARDIOVASCULAR / METABOLISM / OTHER
US 	813 	935 	-13.1% 	-13.1% 	- 	3,192 	3,509 	-9.0% 	-9.0% 	-
Intl 	261 	317 	-17.8% 	-16.0% 	-1.8% 	1,268 	1,369 	-7.4% 	-10.9% 	3.5%
WW 	1,074 	1,253 	-14.3% 	-13.8% 	-0.5% 	4,460 	4,878 	-8.6% 	-9.6% 	1.0%
XARELTO
US 	644 	629 	2.5% 	2.5% 	- 	2,438 	2,345 	4.0% 	4.0% 	-
Intl 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
WW 	644 	629 	2.5% 	2.5% 	- 	2,438 	2,345 	4.0% 	4.0% 	-
INVOKANA / INVOKAMET
US 	59 	159 	-63.1% 	-63.1% 	- 	308 	564 	-45.4% 	-45.4% 	-
Intl 	60 	58 	3.8% 	4.5% 	-0.7% 	254 	231 	9.9% 	5.4% 	4.5%
WW 	120 	217 	-45.1% 	-44.9% 	-0.2% 	563 	795 	-29.3% 	-30.6% 	1.3%
PROCRIT / EPREX
US 	55 	62 	-12.8% 	-12.8% 	- 	223 	277 	-19.7% 	-19.7% 	-
Intl 	58 	66 	-13.0% 	-11.7% 	-1.3% 	256 	274 	-6.8% 	-10.1% 	3.3%
WW 	113 	129 	-12.9% 	-12.2% 	-0.7% 	479 	552 	-13.3% 	-14.9% 	1.6%
OTHER
US 	55 	85 	-35.6% 	-35.6% 	- 	223 	323 	-31.0% 	-31.0% 	-
Intl 	143 	194 	-25.9% 	-23.8% 	-2.1% 	758 	864 	-12.2% 	-15.5% 	3.3%
WW 	198 	278 	-28.9% 	-27.4% 	-1.5% 	981 	1,186 	-17.3% 	-19.7% 	2.4%
TOTAL PHARMACEUTICAL
US 	7,418 	7,116 	4.2% 	4.2% 	- 	27,954 	25,735 	8.6% 	8.6% 	-
Intl 	6,870 	5,152 	33.4% 	36.9% 	-3.5% 	24,126 	19,837 	21.6% 	18.8% 	2.8%
WW 	14,288	$ 	12,268 	16.5% 	17.9% 	-1.4% 	52,080	$ 	45,572 	14.3% 	13.1% 	1.2%
% Change 	% Change

-- 18 of 20 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
MEDICAL DEVICES SEGMENT (2) 	2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
INTERVENTIONAL SOLUTIONS
US 	483	$ 	433 	11.6% 	11.6% 	- 	1,836 	1,452 	26.4% 	26.4% 	-
Intl 	536 	460 	16.5% 	18.8% 	-2.3% 	2,135 	1,594 	34.0% 	29.8% 	4.2%
WW 	1,019 	893 	14.1% 	15.3% 	-1.2% 	3,971 	3,046 	30.4% 	28.2% 	2.2%
ORTHOPAEDICS
US 	1,305 	1,352 	-3.5% 	-3.5% 	- 	5,126 	4,779 	7.3% 	7.3% 	-
Intl 	851 	839 	1.5% 	3.9% 	-2.4% 	3,462 	2,984 	16.0% 	12.1% 	3.9%
WW 	2,155 	2,191 	-1.6% 	-0.7% 	-0.9% 	8,588 	7,763 	10.6% 	9.1% 	1.5%
HIPS
US 	229 	229 	0.4% 	0.4% 	- 	883 	793 	11.4% 	11.4% 	-
Intl 	151 	143 	4.9% 	6.5% 	-1.6% 	602 	487 	23.6% 	18.9% 	4.7%
WW 	380 	372 	2.1% 	2.7% 	-0.6% 	1,485 	1,280 	16.0% 	14.3% 	1.7%
KNEES
US 	208 	216 	-4.2% 	-4.2% 	- 	787 	743 	5.9% 	5.9% 	-
Intl 	135 	129 	4.6% 	6.5% 	-1.9% 	538 	427 	26.1% 	21.7% 	4.4%
WW 	342 	345 	-0.9% 	-0.2% 	-0.7% 	1,325 	1,170 	13.3% 	11.7% 	1.6%
TRAUMA
US 	467 	454 	2.8% 	2.8% 	- 	1,819 	1,648 	10.4% 	10.4% 	-
Intl 	261 	268 	-2.4% 	0.7% 	-3.1% 	1,066 	966 	10.4% 	7.1% 	3.3%
WW 	728 	722 	0.9% 	2.0% 	-1.1% 	2,885 	2,614 	10.4% 	9.2% 	1.2%
SPINE, SPORTS & OTHER
US 	401 	453 	-11.4% 	-11.4% 	- 	1,637 	1,595 	2.6% 	2.6% 	-
Intl 	304 	299 	2.0% 	4.3% 	-2.3% 	1,256 	1,104 	13.8% 	9.9% 	3.9%
WW 	706 	752 	-6.1% 	-5.2% 	-0.9% 	2,893 	2,699 	7.2% 	5.6% 	1.6%
% Change 	% Change

-- 19 of 20 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
SURGERY
US 	986 	1,002 	-1.7% 	-1.7% 	- 	3,867 	3,249 	19.0% 	19.0% 	-
Intl 	1,527 	1,427 	7.0% 	8.7% 	-1.7% 	5,945 	4,983 	19.3% 	15.6% 	3.7%
WW 	2,513 	2,429 	3.5% 	4.4% 	-0.9% 	9,812 	8,232 	19.2% 	17.0% 	2.2%
ADVANCED
US 	457 	456 	0.5% 	0.5% 	- 	1,761 	1,535 	14.9% 	14.9% 	-
Intl 	735 	660 	11.2% 	12.6% 	-1.4% 	2,861 	2,304 	24.1% 	20.0% 	4.1%
WW 	1,192 	1,116 	6.8% 	7.6% 	-0.8% 	4,622 	3,839 	20.4% 	18.0% 	2.4%
GENERAL
US 	528 	546 	-3.4% 	-3.4% 	- 	2,105 	1,714 	22.7% 	22.7% 	-
Intl 	793 	767 	3.4% 	5.3% 	-1.9% 	3,085 	2,679 	15.2% 	11.8% 	3.4%
WW 	1,321 	1,312 	0.6% 	1.7% 	-1.1% 	5,190 	4,392 	18.1% 	16.1% 	2.0%
VISION
US 	443 	397 	11.4% 	11.4% 	- 	1,857 	1,557 	19.3% 	19.3% 	-
Intl 	728 	679 	7.2% 	10.8% 	-3.6% 	2,831 	2,362 	19.8% 	18.8% 	1.0%
WW 	1,171 	1,076 	8.7% 	11.0% 	-2.3% 	4,688 	3,919 	19.6% 	19.0% 	0.6%
CONTACT LENSES / OTHER
US 	316 	289 	9.4% 	9.4% 	- 	1,398 	1,213 	15.2% 	15.2% 	-
Intl 	518 	507 	1.9% 	5.8% 	-3.9% 	2,043 	1,781 	14.7% 	14.0% 	0.7%
WW 	833 	796 	4.6% 	7.1% 	-2.5% 	3,440 	2,994 	14.9% 	14.5% 	0.4%
SURGICAL
US 	126 	108 	16.8% 	16.8% 	- 	459 	344 	33.5% 	33.5% 	-
Intl 	211 	172 	22.9% 	25.4% 	-2.5% 	788 	581 	35.7% 	33.3% 	2.4%
WW 	338 	280 	20.5% 	22.1% 	-1.6% 	1,248 	925 	34.9% 	33.4% 	1.5%
TOTAL MEDICAL DEVICES
US 	3,216 	3,184 	1.0% 	1.0% 	- 	12,686 	11,036 	14.9% 	14.9% 	-
Intl 	3,643 	3,405 	7.0% 	9.3% 	-2.3% 	14,374 	11,923 	20.6% 	17.3% 	3.3%
WW 	6,859	$ 	6,589 	4.1% 	5.3% 	-1.2% 	27,060	$ 	22,959 	17.9% 	16.2% 	1.7%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
The Company estimates that the inclusion of an additional week in the 2020 fiscal year impacted fiscal fourth quarter 2021 comparative sales growth by
approximately -4% and impacted full year fiscal 2021 comparative sales growth by approximately -1%.
% Change 	% Change

-- 20 of 20 --